© 2019 Mission Bay Capital. All rights reserved.

MANAGEMENT TEAM

Douglas Crawford, PhD

Managing Director, Mission Bay Capital
General Manager, MBC Biolabs

Douglas Crawford’s goal is to help entrepreneurial scientists create successful startups. To this end, Doug and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Doug created and manages MBC BioLabs. This state-of-the-art co-working laboratory program in San Francisco allows entrepreneurs to rapidly generate data without getting bogged down in facility management. Rather than spending months getting a facility up and running, MBC BioLabs startups can generate important data in their first week. 

In the first 4 years, this program has helped launch 104 companies that have raised over 1.76B. This incubator program reflects Doug’s passion for startups and his eagerness to help entrepreneurs overcome challenges.  

 

Doug is also the Managing Director of Mission Bay Capital and has overseen the investment in 45 companies, 9 of which have already enjoyed successful exits (Alector, Atreca, Calithera, Cell Design Labs, iPierian, Principia, Redwood Biosciences, True North, and Zephyrus). He is a board member of Avexegen, Epiodyne, Graphwear, Invenio, Magnamosis, Magnap, Mitokinin, SiteOne (observer), and Tangible Sciences.

 

Doug received his PhD in biochemistry from UCSF.

Robert Blazej, PhD

Partner, Mission Bay Capital
Director, MBC Biolabs

Robert is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation.

 

For the previous four years, Robert directed Novozymes’ Digital Biotechnology unit in San Francisco and their global biotechnology scouting team. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that mircrodoplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013.

 

Robert earned his Ph.D. in 2006 in Bioengineering jointly from UC Berkeley and UC San Francisco. His graduate research focused on the design, implementation and characterization of microfluidic systems for next-generation DNA sequencing. Blazej is a published contributor to the human, drosophila, and canine genome projects, with his work on integrated microfluidic DNA sequencing featured on the cover of PNAS and in Nature.

Peter D. Parker

Venture Partner, Mission Bay Capital
Managing General Partner, BioInnovation Capital

Peter is a Venture Partner at Mission Bay Capital and Managing General Partner of BioInnovation Capital. For nearly 20 years, Peter Parker was a General Partner at Ampersand Capital Partners, Wellesley MA, where he co-led the firm’s Life Sciences activities. 

 

For the past several years, Peter has played a major role in the greater Boston/Cambridge life sciences start-up community.  At MassChallenge, he was the healthcare/life sciences ‘Champion’ for that Boston accelerator for five years.  He is a co-founder of BioInnovation Capital, Cambridge BioLabs and the BioLabs network, and is a member of several Angel investing groups. Together with Johannes Fruehauf he has launched LabCentral, Inc., a major addition to the life sciences start-up ecosystem on the East coast.  


From 2006–2010 he was President and CEO of Cequent Pharmaceuticals (sold to Marina Biotech). He has served as a director of numerous companies including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex, Castlewood Surgical and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, BioEssences and TekCel. Prior to Ampersand, Peter spent fourteen years at AMAX, Inc. Peter Parker holds BS and MS degrees from Columbia University.

Harold E. “Barry” Selick, PhD

Venture Partner

In addition to his role at Mission Bay Capital, Barry Selick is Vice Chancellor for Business Development, Innovation and Partnerships at the University of California, San Francisco (UCSF). Prior to joining UCSF, he was the CEO of Threshold Pharmaceuticals, a NASDAQ-listed biotech company which he led from its initial venture capital financing in 2002 until March 2017. He was also a Venture Partner at Sofinnova Ventures from June 2002 until July 2007. Prior to Threshold, Barry co-founded and was CEO of Camitro, a venture-backed biotech company located in Menlo Park, CA, as well as founded and was Chairman of Camitro UK, Ltd., located in Cambridge, UK. Both companies were acquired by ArQule 2 years after founding. Before Camitro, Barry was at Affymax Research Institute, which was acquired by Glaxo Wellcome, plc as its drug discovery technology development center and where Barry was Vice President of Research, responsible for technology development and drug discovery. Prior to Affymax, Barry was a Staff Scientist and Senior Scientist, respectively, at Protein Design Labs (PDL) and Anergen. While at PDL, he, along with Cary Queen, invented the technology for humanizing mouse monoclonal antibodies as therapeutics and applied that to daclizumab, the first FDA-approved fully humanized antibody therapeutic, that was licensed to and commercialized by Roche for the prevention of kidney transplant rejection. Approximately 16 different therapeutics benefitting patients with a variety of cancers, as well as inflammatory, respiratory, and autoimmune diseases have subsequently been developed based on this technology.

 

With a BA in Biophysics and PhD in Biology from the University of Pennsylvania, Barry was a Damon Runyan-Walter Winchell Cancer Fund Fellow as well as a Senior Fellow of the American Cancer Society at UCSF. He has sat on and/or chaired a number of Boards of Directors of both private and public biotech companies.

Linda Eng

Office Manager, Mission Bay Capital
Business Manager, MBC Biolabs

Linda Eng is Office Manager for Mission Bay Capital, helping the team track investment deals, organize meetings, and provide administrative support. Linda is also Business Manager for QB3@953, a state-of-the-art laboratory incubator, where she manages space and lease interactions, application processes, and faciliites.

She served as assistant to Douglas Crawford at QB3 years ago, where she helped Mission Bay Capital in its formation and launch. Thereafter, Linda was offered a role within UCSF's Department if hematology and oncology as Program Manager of the Translational Research Program under the Alliance for Clinical Trials in Oncology, an NCI cooperative group. She managed the requests, approval process, and regulatory requirements for translational studies of biospecimens from all tumor types from the Alliance's federated biorepositories. While there, her role grew into Program Manager of the Prostate Cancer Research Program for UCSF's Helen Diller Family Comprehensive Cancer Center. Linda provided project management for a $10M Stand Up To Cancer Prostate Dream Team, a six-institution clinical trial effort to target treatment-resistant metastatic prostate cancer.

Linda enjoys reading, science fiction movies, British TV, time with family, and traveling. 

Vivian Dang

Controller

Vivian Dang brings over 17 years of finance and taxation experience to Mission Bay Capital where she has been part of the team since 2010. As a part-time CFO, Vivian handles various finance and operational tasks. Prior to starting her own financial operations firm, Vivian was a controller at Mohr Davidow Ventures. She began her career at Andersen and Deloitte where she gained extensive experience in tax and audit. Vivian earned her B.S. in Accounting from the University of California Riverside.

Please reload

INVESTMENT ADVISORY COMMITTEE

Brook Byers
Partner
Kleiner, Perkins, Caufield & Byers
John Wadsworth, Jr
Managing Director
Manitou Ventures
Brian Atwood
President and CEO,
Cell Design Labs
Chris Christoffersen, PhD
Partner
Morgenthaler Ventures
Luke Evnin, PhD
Managing Director
MPM Capital
Wende Hutton
General Partner
Canaan Partners
Fred Cohen MD PhD
General Partner TPG Ventures
and Professor, UCSF
Jonathan Root, MD
General Partner
US Venture Partners
Show More